We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Venture Life Group Plc | LSE:VLG | London | Ordinary Share | GB00BFPM8908 | ORD 0.3P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 36.75 | 36.00 | 37.50 | 36.75 | 36.75 | 36.75 | 64,272 | 08:00:23 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Misc Retail Stores, Nec | 43.98M | 520k | 0.0041 | 89.63 | 46.24M |
Date | Subject | Author | Discuss |
---|---|---|---|
09/1/2019 08:27 | Blimey see what you mean Jane.Definitely some signs of life in the market more broadly. | hydrus | |
09/1/2019 08:25 | something odd at prsm today; no idea what yet : trading now resumed. most odd | janeann | |
09/1/2019 07:49 | Another materially ahead statement, this time at SCT - share price fall from September seems overdone. | valhamos | |
08/1/2019 23:07 | I dont know Red We're not out of the woods yet.. Might be able to buy them back a lot cheaper. But then again who knows these days!! P.s getting board of the guessing through the instability. might switch off till its decided if its the union flag or the blue one with gold stars flying over the tower :) | thelongandtheshortandthetall | |
08/1/2019 20:28 | Bloomberg @business Follow Follow @business More 'Growth in Mercedes car deliveries tumbled to the lowest in a decade last year.' Looks my friend from new years eve was spot on. best to avoid car sales co's. for the time being. But if your in the market for a new car then you'll probably get a bargain if you squeeze a little. | thelongandtheshortandthetall | |
08/1/2019 17:55 | Been falling all my life, tlst. The consequence of 'punching above your weight' is that you get floored! apad😡 | apad | |
08/1/2019 17:11 | Think the £ is going to fall for a couple of days. Yes its probably obvious.. :) | thelongandtheshortandthetall | |
08/1/2019 13:33 | "Sometimes I wish I could lock down certain shares on my SIPP, those that I've decided to be a VLTH in and wish to hide away and forget - experience shows that's sometimes the best way to invest in them, and lose out on trying to trade in them." Couldn't agree more, it's the core of my investment policy. The problem is that the number of stars are limited and that they do sometimes fall of their perch. So, one cannot be completely hands-off. I check out HLMA on their FY, in a pretty cursory fashion. It's enough and I don't expect to sell them ever. ABC looked to be similar but there is clear evidence that they have mismanaged their software development, so I now look more closely. I went from ICI to Zeneca to Astra Zeneca and the story is clearly very different now, from when ICI was a stalwart. The past doesn't predict the future, but good business models exercised by powerful companies can last for a long time. apad | apad | |
08/1/2019 13:27 | The impression I get from another very small non listed company but very similar in how it works to arc is that money is fairly tight at present and new business isnt being one easily because of the wider market jutters/brexit etc. But in time new business should come arcs way and it will be diofficult to buy onany announcement. A few small trades also triggers a bit of a spike from which the share price reverts back to previous level. Not that I am keen to trade arc either | janeann | |
08/1/2019 13:15 | ARC - think all's very clear at the moment. Will keep ear to the ground, but ARC's a very quiet company. Sometimes I wish I could lock down certain shares on my SIPP, those that I've decided to be a VLTH in and wish to hide away and forget - experience shows that's sometimes the best way to invest in them, and lose out on trying to trade in them. In other words, am own worse enemy sometimes. | cooltools | |
08/1/2019 12:59 | OT) Please look at Futura Medical (FUM) has a dirt low market cap of 19 Million and has 3 Drugs including a potential MEGA Blockbuster in Phase 3 for the treatment of erectile dysfunction which works way faster than market leaders like Viarga and Cialis . If you look for a potential 10+ Bagger then load up FUM stock alreay jumping higher check it out guys Research Confirms MED2002's US$1 Billion Potential hxxps://futuramedica The latest market research further endorses Futura's strategy of developing MED2002 as a prescription product in standard and increased strength dose forms, with the objective of switching the standard dose form to an OTC product at an appropriate time. Ipsos's validated healthcare forecasting model was used to predict peak OTC annual sales for MED2002 in key countries worldwide in excess of US$650 million. This forecast follows earlier market research commissioned into the potential of MED2002 as a prescription product, which indicated a prescription market size of up to US$600 million in key countries worldwide. Ipsos forecasts that 70% of OTC product sales will be incremental to the prescription ED category. As a result, the estimated peak annual sales of MED2002 in prescription and OTC versions is predicted to be more than US$1 billion prior to the expiry of the product's expected patent life. The Ipsos valuation was based on the outcomes from primary market research carried out amongst 400 men with ED or suspected ED in the USA. The respondents were in four groups: satisfied users of PDE5 inhibitors (the class of drugs such as Viagra and Cialis); dissatisfied users of PDE5 inhibitors; diagnosed but untreated ED sufferers; and suspected though undiagnosed ED sufferers. The respondents were shown a concept about MED2002 as part of the market research though they did not use the product as it is currently in clinical development. The key findings of the market research showed that the respondents believed that the product, once approved, is highly differentiated from existing products and that its claims would meet their needs. MED2002's rapid onset of action, an average of less than five minutes, was the key feature that attracted respondents to the product and could command a price premium compared with existing ED treatments, which have a substantially slower onset of action. The Ipsos healthcare forecasting model has been demonstrated by Ipsos to be within 20% of actual sales volumes in 9 out of 10 of its forecasts. Pipeline hxxps://www.futurame MED2002 (topical treatment for erectile dysfunction) hxxps://futuramedica first patient dosed: in Q3/Q4 2018 Last patient dosed: by end of June 2019 Headline efficacy results: by end of December 2019 CSD500: Erectogenic condom hxxps://futuramedica Significant milestone achieved with approval of 2-year shelf life approved for CSD500, the erectogenic condom in September 2018. Development now complete. Discussions are ongoing with current and potential further distribution partners on next steps with the product in a number of markets. Pain relief products: TPR100 (diclofenac) and TIB200 (ibuprofen) hxxps://futuramedica TPR100 commercial partner Thornton & Ross filed for UK regulatory submission in July 2018. Out-licensing discussions for TPR100 outside of the UK are ongoing. | bioking | |
08/1/2019 12:28 | Thanks for the NXT headsup a week ago, it's doing nicely now, ticking up every day. Put 5% of SIPP on it, one happy bunny! Cheers! | cooltools | |
08/1/2019 11:16 | Comparison starting at a gallop (of course): Lauders, Red and apad leading, in that order. What do they say about strong starters? Hmm...... We shall see. Plenty of time left! CKN having a good start to the year. Don't hold but always interested in how it does as it is a shipping company and gives an idea about world trade. | lauders | |
08/1/2019 11:15 | Bought some SSON and Fundsmith global earlier. just a small step back in. re balancing really. | thelongandtheshortandthetall | |
08/1/2019 11:11 | New Joel Greenblatt vid always worth a watch: | thelongandtheshortandthetall | |
08/1/2019 09:09 | ps Both SOS and PTSG are below recent placing prices. | apad | |
08/1/2019 09:06 | Mr. M unimpressed by ABC. Looks like my top-slicing was sensible. I wouldn't be inclined to increase until their software project has finished and margins improve. It's still the gorilla. SOS still responding well to Scott's comments and BOO has regained its momentum ahead of next week's update. Comparison starting at a gallop (of course): Lauders, Red and apad leading, in that order. Malcy opines that February will be a busy month for AMER, with the CEO doing the rounds of institutions pedalling his 'good news' wares. apad | apad | |
08/1/2019 07:54 | Knew I should have swapped spe for ztf in the comparison Sopheon, the international provider of software, expertise, and best practices for enterprise innovation management solutions, announces that it is partnering with global confectioner The Hershey Company (NYSE:HSY) to support digital transformation of Hershey's product innovation portfolios. | janeann | |
07/1/2019 19:47 | Lol well it's a £2.7bn company so any stake under say £25m would be very easy to unload. | hydrus | |
07/1/2019 18:51 | Tongue in cheek, Hydrus, but I have rather a lot of shares and if a knight in shining armour wanted to buy them all it would solve the problem of feeding them into the market.... Gulp! apad😊 | apad | |
07/1/2019 18:46 | APAD if you want a takeover that suggests you really think you should sell. Not sure it's worth you just hanging in in the hope for maybe a 20% - 30% premium? That's a long shot anyway. | hydrus |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions